Technology evaluation: BL22, NCI.
BL22 (RFB4(dsFv)-PE38) is a recombinant Pseudomonas exotoxin-based immunotoxin under development by the National Cancer Institute for the treatment of B-cell malignancies. It is composed of the disulfide-stabilized Fv portion of the anti-CD22 antibody RFB4 genetically fused to a truncated form of Pseudomonas exotoxin A. It has entered phase I trials for the treatment of B-cell lymphoma.
Barth
Stefan
S
Institute of Biology, Aachen, Germany. barth@molbiotech.rwth-aachen.de
D000818:Animals; D000906:Antibodies; D002986:Clinical Trials as Topic; D004768:Enterotoxins; D006801:Humans; D007167:Immunotherapy; D000922:Immunotoxins / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D015448:Leukemia, B-Cell / Q000276:immunology / Q000628:therapy; D007943:Leukemia, Hairy Cell / Q000276:immunology / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011549:Pseudomonas
D000906:Antibodies; D004768:Enterotoxins; D000922:Immunotoxins; C431326:RFB4(dsFv)-PE38 recombinant immunotoxin